Quale sarebbe il prezzo per Entropy Neurodynamics Limited (ENP)

Il prezzo per Entropy Neurodynamics Limited (ENP) è $0.02468497

Qual è la capitalizzazione di mercato per Entropy Neurodynamics Limited (ENP)

La capitalizzazione di mercato per Entropy Neurodynamics Limited (ENP) è $40.28M

Entropy Neurodynamics Limited (ENP) Azioni in Circolazione

Entropy Neurodynamics Limited operates as a clinical-stage pharmaceutical company, dedicated to pioneering novel formulations for psilocin administration. These formulations are intended for use alongside psychotherapy, aiming to tackle medical conditions with pressing unmet needs across Australia, Canada, Switzerland, and the United States. The firm's flagship development is TRP-8803, an intravenously infused psilocin formulation that has successfully concluded Phase 2 clinical trials. These trials investigated its potential to treat binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. Additionally, the company is advancing TRP-8802, a synthetic, orally administered psilocybin compound. TRP-8802 is currently undergoing Phase 2a clinical trials for binge eating and is in Phase 2 clinical development for fibromyalgia and irritable bowel syndrome. Established in 2019 and headquartered in Camberwell, Australia, the company adopted its current name, Entropy Neurodynamics Limited, in November 2025, having previously operated as Tryptamine Therapeutics Limited.

Anno	Azioni in circolazione	Cambia
Non abbastanza dati per le date fornite.

Anno

Azioni in circolazione

Cambia

Non abbastanza dati per le date fornite.

Azienda	Azioni in circolazione	Differenza	Il paese
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	-	US
Argenx SE ARGX.US	62.19M	-	NL
CSL Limited CSL.AX	483.58M	-	AU
Moderna, Inc. MRNA.US	396.00M	-	US
Lonza Group AG LONN.SW	-	-	CH

Azienda

Azioni in circolazione

Differenza

Il paese